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Methicillin-resistant Staphylococcus aureus (MRSA), drug-resistant bacterial infection, is 
a pressing global health care issue that decreases patients’ quality of life and places a 
high burden on health care delivery systems.  The purpose of this quality improvement 
evaluation project was to evaluate an infection prevention management program derived 
from evidence-based research to decrease the incidence of MRSA in peripherally inserted 
intravenous catheters (PIVs) in acute care settings through the utilization of the Biopatch 
disc. The practice-focused question addressed whether the use the Biopatch disc over a 6-
month period in acute care would coincide with a reduction of the incidence of MRSA 
infection in PIVs.  The number of MRSA infections at the hospital project site during a 
30-day pre-implementation period was compared to those during 2 post-implementation 
phases of Biopatch disc usage. Deming’s model for continuous quality improvement 
served as the conceptual framework.  Data were analyzed using the Fisher’s exact test.  
The plan, do, study, and act phases of Deming’s model were used in a rapid-cycle format 
during the evaluation, which allowed for changes in protocol as feedback was gathered.  
Results suggest that the Biopatch disc could possibly decrease the incidence of MRSA in 
PIVs when utilized according to organizational protocols. Infection prevention, quality 
improvement, and risk management teams should be able to collaborate and develop 
local and regional surveillance programs based on use of the Biopatch.  This project had 
the potential to effect positive social change by improving the quality of life and safety of 
patients in acute care setting, and by reducing costs of healthcare overall so as to promote 
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Section 1: Nature of the Project 
Intravenous (IV) catheters have been one of the most customary and frequently 
used interventions for IV therapy in medical care.  Although this therapy method seems 
simple and most effective, it was not without health risks.  Skin penetrating devices such 
as IV catheters can act as a portal of entry for infectious organisms to enter the body and 
increase patients’ risk for infection.  IV catheters are reported to be the single most 
common source of bacteremia and fungemia worldwide, yet infections associated with 
short peripheral catheters have received very little attention (Hadaway, 2012).  The 
medical benefits for intravascular devices (e.g., peripherally inserted intravenous 
catheters [PIVs]) should be carefully considered against both the infectious and 
noninfectious risks (Mutters, Gunther, Heininger, & Frank, 2014). The establishment of 
an environment free of methicillin resistant staphylococcus aureus (MRSA) as part of an 
infection prevention protocol in an acute care setting has been found to yield positive 
results (Mutters, 2014). 
Problem Statement 
IV catheters have been the most frequently used interventions for IV therapy in 
medical care.  This method of therapy is simple and frequently used, but it does not come 
without other potential health risks.  Devices that penetrate the skin, such as IV catheters, 
create a portal of entry for infectious agents to enter the body, therefore increasing the 
patient’s risk for infection ((Hadaway p.2012).  Although the number of patients who 
receive short peripheral catheter therapy is far greater than those with central venous 
catheter access devices, the rate of infection associated with the short PIV is very low, 
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according to Hadaway (2012). It is important to note that scientific data related to the 
infection rate of short peripheral catheters is limited (Hadaway, 2012).  
A recent report cited as many as 10,000 staphylococcus aureus bacteremia due to 
the usage of PIVs in the United States (Hadaway, 2012).  Experts view the conflicting 
data to be related to short dwell time and early patient discharge ((Hadaway p.2012).  In 
other IV access devices, the Biopatch disc was shown to be an effective tool in 
decreasing MRSA in peripherally inserted central catheter (PICC) lines as well as in 
central venous lines (CVL) ((Hadaway p.2012).  However, there is currently no 
surveillance tool available to show the effectiveness of the Biopatch disc on PIVs, based 
on my review of the literature.  The problem that was addressed in this evaluation project 
was the lack of knowledge regarding whether the Biopatch disc would be effective in 
preventing infections in patients with PIVs. 
Purpose 
The published rates, causes, and prevention of infections associated with short 
peripheral catheters needed more clarity.  Improving patient outcomes was the driving 
force behind the implementation of this project. Healthcare in general and the nursing 
profession, specifically, should advocate for the safety of the patients within their care.  
Relevant literature suggested that the best approach for tackling the problem of MRSA is 
through active surveillance of high-risk patients or during the times when the potential is 
greatest by adopting simple perioperative practices to reduce the incidence of MRSA 
infection and, in turn, its emergent resistance (Byrne, Hazlerigg, Khan, & Smitham, 
2011).  The purpose of this evaluation project was to assess the current practices of using 
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the Biopatch disc on PIVs and to determine the association with the incidence of MRSA 
in patients in acute care settings. 
The practice-focused question that was used to help guide the evaluation project 
was, In the acute care setting, would using the Biopatch disc reduce the risk of MRSA 
infection when used on peripheral IV catheters over a 6-month period? The goal of the 
evaluation was to provide evidence regarding whether the use of the Biopatch disc 
decreased the incidence of MRSA in PIVs in patients in acute care settings over a 6-
month period.  The results of the quality improvement evaluation showed reliability.  
Evidence of the reliability may compel other healthcare professionals and the infection 
prevention (IP), quality improvement (QI), and risk management (RM) teams of acute 
care organizations to collaborate and develop local and regional surveillance programs. 
These programs, along with other existing initiatives to educate nursing staff and other 
personnel on the incidence of decreasing MRSA, may lead to reduction in the number of 
MRSAs in acute care settings.  Furthermore, the evaluation findings empower the local 
hospital/acute care setting to make the necessary changes within its IP, QI, and RM 
programs to independently develop a surveillance program to further decrease rates of 
MRSA in PIVs within the organization. 
Nature of the Doctoral Project 
The quest to find the right combination of preventive measures and interventions 
to decrease patients’ incidence of MRSA in PIVs in the acute care setting continues to 
evade the nursing profession.  There was a limited amount of literature dedicated to 
peripheral IV therapy and MRSA (e.g., Serane & Kothendaraman, 2016) and a limited 
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number of options available for healthcare personnel to use to decrease MRSA in PIVs.  
The documented research on current EBPs developed with the intent of mitigating this 
problem is readily available to support measures that can be implemented in preventing 
MRSA (e.g., Serane & Kothendaraman, 2016).  Although any infection prevention 
program must be an interdisciplinary strategy; MRSA is still considered a nursing quality 
indicator. 
The main topic that was identified in the literature on MRSA was the need for a 
tool to thoroughly and accurately assess and identify at-risk patients and a strategy to 
prevent and control infections in the acute care setting (Serane & Kothendaraman, 2016).  
The rate of infections associated with short PIVs was believed to be very low--even rare 
in the same instances (Hadaway, 2012).  The available literature focused on a more 
comprehensive preventive strategy aimed at implementation of a specific anti-infective 
measure such as the use of the Biopatch disc (Hadaway, 2012).  There is, however, a 
growing body of recent literature that addresses the incidence of MRSA in other 
indwelling devices as it relates to hospital-acquired infections (HAIs); Mutter, 2014).   
This DNP project was an evaluation of an implemented Phase I and Phase II 
quality improvement program that was implemented in 2016.  In the case of this program, 
all the patients that were admitted on a general oncology and medical surgical unit were 
included in a 6-month Phase I implementation program.  All staff of the nursing units in 
the program were trained in utilizing the Biopatch disc with PIVs to decrease the 
incidence of MRSA.  
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I used a convenience sample method based on the inpatient population of the 
nursing units.  Convenience sampling is a type of nonprobability sampling that includes 
participants who were in place at the time of the study; it is the most widely used method 
in nursing research studies (Burns & Grove, 2009).  I used historical and concurrent data 
that had previously been collected by the IP, QI and RM teams to evaluate trends in the 
project organization’s practices and incidence of MRSA. 
The outcome that was compared was the incidence of MRSA in PIVs in patients 
who were admitted to the Oncology and Medical-Surgical units, in which the Biopatch 
disc was utilized, compared to those patients who did not utilize the Biopatch disc. I 
analyzed whether the Biopatch disc was effective in meeting the objectives of decreasing 
the incidence of MRSA in PIVs for patients admitted to these units.  Findings showed 
whether the Biopatch disc was beneficial in decreasing MRSA in PIVs for patients who 
were admitted to those units. 
The detection of patient risks nursing theory was the framework used for the 
development of this MRSA risk/prevention program.  The goal of the project was to 
evaluate if there was a decrease in the incidence of MRSA in patients with PIVs by using 
the Biopatch disc by 50% over a 6-month time frame during Phase I of the implemented 
pretrial program.  The Biopatch disc implementation was accomplished by creating an 
implementation plan in collaboration with clinical leaders, educating/in-servicing of 
admissions in the inpatient areas, and through point prevalence follow up to identify 
additional educational needs.  The Agency for Healthcare Research and Quality (AHRQ) 
has been supportive of the movement towards creating high reliability in healthcare to 
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improve the quality and safety of care delivery (Blouin & McDonagh, 2011).  Being 
designated a high-reliability organization is what most organizations would like to 
achieve; however, the framework has had only borderline success in the healthcare 
industry (Polonsky, M.S., 2019.  However, when safety and consistency are embedded in 
every aspect of performance, it should ultimately decrease the number of infections 
within an organization. 
Initiating a surveillance program in the acute care setting contributes 
understanding of how indicators are detected, which is important to ensure optimal 
patient outcomes.  The patient outcomes that were realized through this initiative were 
the true driving force behind this implementation.  Being a nurse in the healthcare arena, 
we should advocate for the overall safety of the patients trusted in our care.  The new 
evidence-based best practices and guidelines for PIV catheter management were not well 
disseminated within the medical community of practice and presented a serious 
knowledge gap, with the potential to negatively impact patient safety and decrease 
quality of care and patient outcomes. 
Significance 
In conducting the project, I evaluated the outcomes pre- and postimplementation 
of the Biopatch disc at the medical facility, utilizing the historical and concurrent data 
that had already been collected by the IP, QI, and RM teams.  The information provided 
was used to evaluate trends in decreasing MRSA in patients with PIVs. 
The methodology for the project consisted of a review of data from patients who 
were admitted to the facility and received a PIVs without the use of the Biopatch disc 
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versus those who were admitted and received a PIV utilizing the Biopatch disc. I 
compared incidence of MRSA in the two groups.  This allowed me to evaluate the 
effectiveness of the Biopatch disc on PIVs and whether it resulted in a decrease in the 
incidence of MRSA in PIVs or not over a 6-month period. 
This was a QI project that was implemented in an acute care setting hospital in 
Jefferson County, Birmingham, Alabama, a setting where the number of catheter-related 
PIVs and incidence of MRSA had increased in patients who were admitted and had a 
hospital stay longer than seven days.  IV catheters are one of the most customary and 
frequently used interventions for IV therapy in medical care (Byrne et al., 2011).  Skin-
penetrating devices such as IV catheters can act as a portal of entry for infectious 
organisms to enter the body and increase the patient incidence for infection (Byrne et al., 
2011).  There has been substantial focus on the risks associated with central venous 
catheters, including catheter-related bloodstream infections (Byrne et al., 2011); however, 
PIVs are much more common in acute care setting hospitals and carry a more associated 
risk (Byrne et al., 2011). 
A comparison of the pre- and posttest data sets obtained from the IP, QI, and RM 
team resulted in a better understanding of the problem that impeded MRSA in acute care 
settings.  With this information, I was able to evaluate the effectiveness of the Biopatch 
disc on PIVs.  These data also provided reliable information on how to decrease the 
incidence of MRSA in PIVs and decrease overall patient hospital length of stay to fewer 




MRSA is a part of a strain of resistant beta-lactam antibiotics, including penicillin 
and cephalosporin.  MRSA is the cause of a significant number of HAIs (Byrne et al., 
2011).  Evidence has shown that whenever patients have a break in their natural host of 
defense, they are potentially at risk to be exposed to pathogens from the hospital’s 
environment (Byrne et al., 2011).  The use of the Biopatch disc has had a positive impact 
on decreasing the incidence of MRSA in PIVs in patients admitted to acute care settings 
and has helped to improve patient outcomes (Byrne et al., 2011). 
The published rates, causes, and prevention of infections associated with short 
peripheral catheters needed more clarity.  This information and on patient outcomes may 
enable healthcare practitioners in general, and the nursing profession, specifically, to 
better advocated for the safety of the patients in their care.  The goal of the evaluation 
was to show whether the use of the Biopatch disc decreased the incidence of MRSA in 
PIVs in patients in acute care settings.  The results of this QI evaluation showed 
reliability. Evidence of the reliability may allow other healthcare professionals and the IP, 
QI, and RM teams of acute care organizations to collaborate and develop local and 
regional surveillance programs. These programs, along with other existing initiatives to 
educate nursing staff and other personnel on the incidence of decreasing MRSA, may 
promote patient safety.  Furthermore, they may provide local hospitals/acute care settings 
with the empowerment to make necessary changes within their IP, QI and RM programs 
to develop a surveillance program of their own to decrease their rates of MRSA in PIVs 
within their organizations as well. 
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The medical benefits of an intravascular device should always be considered 
carefully against both the risks and the benefits.  Furthermore, catheters should always be 
removed if there are impeding signs of infection trying to occur or if the device is no 
longer essentially necessary (Austin et al., 2016, para 1).  The large number of PIVs that 
are implemented in acute care settings and the scant attention given to HAI risks 
associated with these lines constitute an urgent consideration of IV therapy (Austin et al., 
2016, para 1).  Although the IV device is an essential component of modern health care, 
it must not be forgotten that its presence could increase the risk of HAIs to recipients.  
Skin flora such as the staphylococci spp are the organisms most associated with line-
related bacteremia and can have potentially fatal consequences for patients (Austin et al., 
2016, para. 1). 
MRSA in PIVs remains a major concern in acute care settings.  Site monitoring 
before and after removal of PIVs should be a priority in preventive efforts to help 
decrease the incidence of MRSA in acute care settings.  Based on my review of the 
literature, more prospective studies are needed, both to assess the true incidence and 
burden of PIV-related bloodstream infections and to evaluate effective innovative 
prevention strategies, such as checklists for PIV insertion, monitoring PIV sites, and the 
use of qualified trained personnel in IV therapy. 
Summary 
In summary, catheter-related bloodstream infections such as MRSA are 
expensive, prevalent, and often fatal. The number of such infections could possibly be 
reduced, and the outcomes can be improved if specific standards in the quality of care are 
10 
 
maintained through a surveillance prevention program.  It is possible to develop 
indicators for mandatory QI programs on MRSA that take into consideration the different 
perspectives of all stakeholders involved.  Ongoing efforts could be put into place to 
increase the prevention of MRSAs and improve the care of those who experience MRSA, 
along with other HAIs, in acute care settings. The number of patients who are affected 
worldwide by MRSA is slowly declining, but not to the point where a significant 
difference can be seen Austin et al., 2016).  Broad use of a QI surveillance program could 
significantly reduce morbidity and costs of care associated with catheter-related 
bloodstream infections such as MRSA in an acute care setting. 
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Section 2: Background and Context 
Prevention of healthcare-associated infections such as MRSA is a major patient 
safety concern worldwide.  Screening of patients for MRSA colonization is becoming a 
routine aspect of hospital admission; however, there is limited published literature as it 
relates to MRSA screenings (Currie, Knussen, Price, & Reilly, 2013).  IV catheters are 
now reported to be the single most common source of bacteremia and fungaemia, but 
infections that are associated with short peripheral catheters have received very little 
attention (Hadaway, 2012).  The medical benefits of an intravascular device (e.g., a PIV) 
should be carefully considered against both the infectious and noninfectious risks 
(Mutters et al., 2014). The establishment of an environment free of MRSA as part of an 
infection prevention protocol in an acute care setting has been shown to yield positive 
results. 
     The problem that was addressed in this evaluation project was the increased incidence 
of MRSA in PIVs in patients in acute care settings.  I undertook the evaluation to address 
the lack of knowledge regarding whether the implementation of the Biopatch disc was 
effective in decreasing the incidence of MRSA in patients with PIVs in acute care 
settings.  The purpose of the project was to evaluate the current practice of using the 
Biopatch disc on PIVs to determine its association with the incidence of MRSA in 
patients in acute care settings. 
In one study, patients receiving IV therapy were four times more susceptible to 
healthcare associated bacteremia than those not receiving this form of intervention 
(Jeanne, Z., 2008).  The increased use of IV therapy throughout medicine has been 
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accompanied by a high incidence of morbidity and mortality associated with catheter-
related sepsis (Waghorn, 1994).  In this doctoral project, I evaluated the effective use of 
the Biopatch disc in reducing the risk of bacteremia infections associated with IV 
catheters in an acute care setting as part of a QI program. The program was recently 
implemented in a Phase I and Phase II within the organization. 
The published rates, causes, and prevention of infection associated with short 
peripheral catheters needs more clarity.  The patient outcomes which was discovered 
through this initiative was the true driving force behind its implementation as healthcare 
in general and the nursing profession advocated for the safety of the patients that was in 
their care.  The theoretical framework, Deming’s (1973) model for improvement, 
supported the idea that the best approach for tackling this problem of MRSA was through 
active surveillance of high-risk patients or during the times of when the potential was 
greatest by adopting simple perioperative practices.  The purpose of this project was to 
evaluate the use of the Biopatch disc on PIVs and its impact on reducing the incidence of 
MRSA in patients in acute care settings. I sought to answer the following practiced-
focused question: In the acute care setting, did using the Biopatch disc reduced the risk of 
MRSA infection when used on PIVs over a 6-month period? 
The goal of the evaluation was to provide evidence regarding whether the use of 
the Biopatch disc decreased the incidence of MRSA in PIVs in patients in acute care 
settings.  The results of this QI evaluation showed reliability; evidence of reliability may 
support collaborations by other healthcare professionals and IP, QI, and RM teams in 
acute care settings organizations to develop local and regional surveillance programs. 
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These programs, along with other existing initiatives, may educate nursing staff and other 
personnel on ways to decrease MRSA.  Furthermore, findings may provide local 
hospital/acute care settings with the empowerment to make necessary changes within 
their IP, QI and RM programs to develop a surveillance program of their own to decrease 
their rates of MRSA in PIVs within their organization. 
Concepts, Models, and Theories 
To increase the likelihood of a program’s success, good planning is critical. The 
model that I chose to guide this project was Deming’s (1973) model for improvement.  I 
used the plan, do, study, and act phases of the model in a rapid cycle format, which 
allowed for changes in the protocol as feedback was gathered and facilitated the use of 
teamwork to make improvements.  Individuals who were admitted to the acute care 
facility and who had a PIV initiated and implemented were at risk for developing MRSA 
within the site.  Educating personnel on the importance of developing a QI plan to stay in 
compliance with the facility policy and procedure protocols may help to reduce the 
increased number of infections and make the jobs of IP, QI and RM team members a 
little easier.   
The theorist who promoted the implemented Phase I of the project was Patricia 
Benner.  Benner viewed that clinical nursing expertise as being embodied; in other 
words, “through experience, skilled performance is transformed from the halting, 
stepwise performance of the beginner…to the smooth initiative performance of the 
expert” (Masters, 2012, p.72).  Benner’s model underpinned the initiative behind the use 
of the Biopatch disc in PIVs in that, through education and training, staff helped to 
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improve their skill performance, from a beginner to the smooth transition of an expert. 
Staff members’ increased efficacy decreased the incidence of MRSA in patients with 
PIVs and improved overall patient satisfaction and outcomes in those who were admitted 
to the acute care facility. 
Professional conduct is socially embedded, wired, and embodied in the practices, 
ways of being, and responses to clinical situations that promote patient well-being, where 
clinical and ethical judgements are inseparable (Masters, 2012).  Benner identified nine 
domains that are critical to patient care and their outcomes.   The domain that best 
correlated to the implemented Phase I and Phase II evaluation of the Biopatch disc in 
decreasing the incidence of MRSA in PIVs was administering and monitoring therapeutic 
interventions and regimens.  One of the core competencies in the healthcare arena is to 
provide an environment that is free of infection as much as possible.  One of Benner’s 
competencies within her domain of administering and monitoring therapeutic 
interventions and regimens included “starting and maintaining intravenous therapy with 
minimal risks and complications” (Masters, 2012, p. 76).  Benner assumed that the 
meaning embedded in skills, practices, intentions, expectations, and outcomes cannot be 
made completely explicit; however, the meaning can be interpreted by someone who 
shares a similar background and can be validated by participants and practitioners 
(Masters, 2012, p. 80).  I implemented this project using a multidisciplinary approach, by 
soliciting stakeholders’ input, identifying key concepts to be communicated, and mapping 
those concepts to Benner’s theory. 
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Definition of Terms 
To ensure understanding of the terms used in this project, the following 
definitions are provided: 
Bacteremia: The presence of bacteria in the bloodstream. 
Client: A customer of a professional service provider or the principal of an agent 
or contractor. 
Educator: A person who provides instruction or education; a teacher. 
Methicillin-resistant Staphylococcus aureus (MRSA): Bacteria that is resistant to 
many antibiotics. 
PIV (peripheral intravenous catheter): A small, flexible tube placed into a vein to 
administer medication or fluids. 
Relevance to Nursing Practice 
MRSA was the cause of a significant number of HAIs (Byrne et al., 2011).  
Attempts had been made to reduce a patient’s risk for contracting any type of infection, 
especially MRSA.  As nursing continues to evolve, it should be a culture of safety in 
which the rates of the HAIs, particularly MRSA have a substantiated decline rate in 
patients in acute care settings.  It has been shown that large-scale QI studies are 
challenging to conduct because they receive less funding than randomized trials that are 
of the same size.  The need to improve the quality of care is too great and the resources 
devoted to such an effort are very limited to be unsure about whether these types of QI 
interventions work.  QI studies require more rigor and resources (Daley, Provost, 
Needham, & Berenholtz, 2007). 
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Catheter-related bloodstream infections are common, costly, and potentially 
lethal.  In the United States, central venous catheters alone caused an estimated 80,000 in 
catheter-related bloodstream infections, thus, up to 28,000 deaths of patients in intensive 
care units (Pronovost et al., 2006).  Per the National Nosocomial Infections Surveillance 
(NNIS) system of the Centers for Disease Control and Prevention, the median rate of 
catheter-related bloodstream infection of all types ranged from 1.8 to 5.2 per 1000 
catheters-days.  Interventions aimed at decreasing the infection rate are needed to reduce 
the serious public health consequences of this HAI (Pronovost et al., 2006). 
PIV insertion is a common procedure among hospitalized patients in acute care 
settings, but few studies have focused on the risk associated with PIV infections (Austin, 
Sean, Whittier, Lowy, & Uhlemann, 2016, para. 1).  Bacteremia as a complication of PIV 
was considered rare and estimated to occur in 0.1 percent of patients with PIV infections.  
However, the large numbers of PIVs that are placed annually mean that the public health 
burden associated with this could even be substantial.  Furthermore, most PIV-related 
bacteremias was related to MRSA and are associated with the most severe complications 
with a mortality rate that could approach 20-30 percent (Austin et al., 2016). The 
significant for nursing practice was indicated by providing evidence-based practice on 
approaches that would decrease MRSA in PIVs in hospitalized patients in acute care 
settings and increased their overall patient outcomes. 
Local Background and Context 
There has been substantial focus on the risks associated with PIV bloodstream 
infections.  PIVs are much more common in acute care settings and have increased 
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associated risks of MRSA.  Peripheral IV catheters allow reliable and convenient delivery 
of life-saving medications for hospitalized patients.  Placement of a peripheral IV 
catheter is, however, a painful experience for patients.  For staff that have limited amount 
of experience in placing peripheral IV catheters, multiple attempts are sometimes 
required, especially for those with difficult venous access, thus making the experience of 
one being very unpleasant. 
IV therapy is a common and frequently vital intervention for patients undergoing 
medical care.  Although this may have a positive effect on the health of the person 
receiving such therapy, it did not come without risks.  Any breach in the integrity of the 
skin, caused by wounds, incisions, or the use of penetrating devices such as intravascular 
catheters, could act as a portal for access to normally sterile tissues by micro-organisms 
and thereby predisposes them to infection. 
Patients receiving IV therapy was four times more susceptible to healthcare-
associated bacteremia than those not receiving this form of intervention (Jeanne, Z., 
2008).  The increased use of intravascular devices throughout treatment has been 
accompanied by significant morbidity and mortality associated with catheter-related 
sepsis (Jeanne, Z., 2008).   
Interest in this form of infection had recently increased.  Bacteremia has now 
become the focus of political attention due to perceived problems of healthcare-
associated infection (Public Health Laboratory service, 2002).  Because of the increase in 
media interest in healthcare-associated infections, there was a perception that these 
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infections were increasing.  Therefore, it was not possible to state whether any increase 
was an actual one or the potential for increase. 
The organization that was being evaluated had a high increase of MRSA within 
their organization when compared to other institutions within the same area.  Local trends 
showed that this organization was worse than the national benchmark when compared to 
other organizations within the same area as it related to MRSA due to failure to follow 
best practices when treating patients with PIVs ("Hospital Compare Quality of Care 
Profile Page," 2017, table 1).   This organization sought out an engineering approach to 
use the Biopatch disc on PIVs to see if it would have a profound affect in decreasing 
MRSA as well.  Although few facilities focused on MRSA in PIVs, bloodstream 
infection (BSI) risk from PIVs may exceed central line-related risk. 
A national surveillance scheme for reporting MRSA as a result, have now been 
established.  To address this situation, the Federal Joint Committee, took a stand, which is 
the highest joint decision-making body of the joint self-government of physicians, 
dentists, hospitals and health insurance funds.  Few studies have focused on the risks of 
PIVs as a source for MRSA, as a life-threatening complication.  National rates of 
catheter-associated bloodstream infections continue to decrease, especially for 
Staphylococcus aureus infections, but little data exist on infections due to peripheral 
catheters.   
Role of the DNP Student 
This evaluation project goal was to improve patient’s safety in acute care settings 
in a local hospital in Jefferson County, in Birmingham, Alabama.  The evaluation focused 
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on the incidence of MRSA in PIVs in patients hospitalized in acute care settings.  The 
goal was to evaluate Phase I and Phase II of this QI project. During Phase I, did the 
implementation of the Biopatch disc utilized with the PIVs reduce the incidence of 
MRSA infections in the 206 medical patients that was admitted in a local hospital in 
Jefferson County in Birmingham, Alabama in 2016. Within 3 months after 
implementation, the median rate of infection was 3, a rate that was sustained throughout 
Phase II of the implementation program.  The role of the DNP educator was to 
collaborate with IP, QI and the (RM) teams to identify indicators that could be evidence-
based as well as being tailored to suit the specific requirements of the organizations 
concerns and which should be implemented on a mandatory basis. 
Summary 
While the IV device is an essential component of modern healthcare, remarkable 
as it is, its’ presence can increase the incidence of healthcare-associated infections in its 
recipients.  Catheter-related bloodstream infections are expensive, prevalent, and often 
fatal. IV therapy continues to be the most frequently used medical procedure for 
hospitalized patients in acute care settings that they continue to experience.  Scrupulous 
aseptic and sterile techniques during the placement and maintenance of such sites can 
prevent catheter-associated complications.  Patients who are in acute care settings are at 
increased incidence for IV catheter-associated infections.  Furthermore, the increased use 
of the device with antibiotics can create a patient care environment where MRSA 
emerges.  Therefore, following the hospital IP, QI, and RM standards and protocols for 
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Section 3: Collection and Analysis of Evidence 
MRSA is a type of staph bacteria that is resistant to many antibiotics. In 
healthcare settings, such as acute care facilities or nursing homes, MRSA can cause 
severe problems, such as bloodstream infections, pneumonia, and surgical site infections 
that could lead to sepsis and death (Centers for Disease Control and Prevention, 2016).  
The focus of the evaluation was on assessing the potential for decreasing the incidence of 
MRSA utilizing the Biopatch disc on PIVs on patients in acute care settings.  When 
healthcare organizations and communities within them can work together to decrease 
HAIs and increase better patient outcomes, they may be better able to reduce the 
incidence of MRSA in acute care settings.  The collaborative efforts between IP, QI and 
the RM teams determined the incidence of MRSA and whether the Biopatch disc 
decreased the incidence in PIVs.  The development of such a collaborative based program 
consisted of educating and training of nursing staff on IV techniques, hand hygiene, and 
infection prevention practices to improve patient outcomes. 
The implementation of a surveillance QI initiative significantly enhanced the 
adherence of prevention guidelines set forth by this evaluation program.  The Centers for 
Disease Control and Prevention had initiated several short- and long-term surveillance 
(infection tracking) programs that involved collaboration with health departments, 
individual hospital, and academic medical centers, among others (Centers for Disease 
Control and Prevention, 2016).  Acknowledging the burden that MRSA had on patient 
outcomes, how frequently it occurred, and how it was spread made it vital for developing 
an effective surveillance prevention program.  The need to improve the quality of care 
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and improve patient outcomes was too great, and the resources devoted to this effort were 
very limited, resulting in uncertainty about whether the QI intervention program really 
worked.  QI initiatives require more rigor and resources.  It was evident that the health 
care community needed more research on this issue to enhance knowledge of infection 
rates, pathophysiology, and the most appropriate preventive methods to utilize. 
Practice-Focused Question 
The practiced-focused question for this evaluation Phase I and Phase II project 
was as follows: In the acute care setting, did using the Biopatch disc reduce the incidence 
of MRSA infection on PIVs over a 6-month period?  The objectives of the project were to 
analyze empirical data to answer the practice-focused question.  Specifically, I wanted to 
answer of whether the facility/organization reduced their incidence of MRSA in patients 
with PIVs who utilized the Biopatch disc in the acute care setting over the 6-month pre- 
and postimplementation time period. 
Sources of Evidence 
There was empirical evidence to suggest that MRSA in PIVs could be reduced 
using the Biopatch disc along with some basic nursing implementation strategies. The 
risk of catheter-related bloodstream infections associated with the use of a central IV line 
or peripherally inserted central catheters was well known and well documented (DeVries, 
Mancos, & Valentine, 2014).  Far less attention had been devoted to the BSI risk from 
PIVs, although that risk might be just as large.  The individual risk of a BSI occurring 
with a PIV is lower than in a central line/peripherally inserted central catheter.  However, 
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some 150 million PIVs are placed in the United States annually, a number that is much 
greater than the number of central lines used overall (DeVries et al., 2014).  
With the approval of the Organization Institutional Review Board, Compliance 
Officer and the Walden Institutional Review Board, (06-12-20-0171452), I evaluated data 
that had previously been collected by a local hospital in Jefferson County in Birmingham, 
Alabama.  The data were compared to a 6-month postimplementation period from July 
2016 to December 2016, when the Biopatch disc was being utilized hospital wide, and to 
the preimplementation period of January 2016 to June 2016, which was also a 6- month 
time interval.  In analyzing these data, I wanted to determine the effect of the Biopatch 
disc on PIVs and the reduction of MRSA.   
A more comprehensive prevention strategy for the implementation of specific 
anti-infective measures such as the Biopatch disc needs to be a part of a broader patient 
safety program.  Indeed, infection control programs are a prototype of safety intervention 
programs within the organization and therefore are responsible for preventing harm to 
inpatients within the acute care setting.  The evidence I reviewed suggests that facilities 
implement a surveillance program to reduce device-related infections (see Mutters et al., 
2014).  One of the most important components of infection control programs is the 
implementation of surveillance programs.  Sources indicated that it is very important to 
identify morbidities, assess infection rates, ensure adherence to preventive measures, and 
identify components of infection control programs (Mutters et al., 2014). 
I analyzed archival data that were collected from a local hospital in Jefferson 
County in Birmingham, Alabama, before and after the Biopatch disc was implemented.  
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My objective was to determine whether there was a significant reduction in MRSA in 
PIVs in patients who were admitted within the acute care setting. Evaluating the 
interventions assisted in determining whether the organizations’ IP, QI and RM programs 
led to a reduction of MRSA in PIVs by implementing the Biopatch disc on patients who 
were admitted in the acute care setting.   
Analysis and Synthesis 
I studied the IP, QI and RM team’s adherence to treatment guidelines using the 
theory of health prevention, as well as the overall effectiveness of decreasing MRSA in 
PIVs using the Biopatch disc in patients in acute care settings.  I based the evaluation on 
the Centers for Disease Control and Prevention Surveillance program for tracking 
infection.  The guidelines suggest that collaboration with health departments, individual 
hospitals, and academic medical centers, among others, are essential for developing 
effective prevention programs and measuring their impact Centers for Disease Control 
and Prevention, 2017, para. 1.  The Centers for Disease Control and Prevention had a 
Category 1A recommendation to evaluate compliance with insertion and maintenance 
protocols for all staff involved with intravascular devices.  Nonetheless, it was 
commonplace for hospitals to not perform such process monitoring on peripheral lines, 
especially those in acute care settings (Centers for Disease Control and Prevention, 2017, 
para. 3). 
However, in support of the Evaluation Plan from the Centers for Disease Control, 
including plans from the state and community-level, the evaluation framework offered 
perspectives for the measurement of components for prevention protocols, as well 
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recommendations for IP and RM Program protocols. The assessment provided evidence 
regarding the effectiveness of using the Biopatch disc on PIVs aimed at preventing 
MRSA in patients in acute care setting 
I obtained and analyzed the following sets of data in in this Phase I and Phase II 
evaluation study: the preprogram MRSA data of the numbers of patients with PIVs 
admitted within the acute care setting without the Biopatch disc and the post program 
MRSA data of the number of patients with PIVs admitted to the same acute care settings 
using the Biopatch disc.  All sets of data were essential in measuring the impact of the 
Biopatch disc in decreasing the incidence of MRSA in PIVs among patients admitted to 
the acute care setting. Data analysis was done using the SPSS Statistics Data Analysis 
package.   The Fischer exact test was most appropriate for this evaluation of PIV utilizing 
the Biopatch disc verses those that did not utilize the Biopatch disc during 
implementation of a PIV and the incidence of MRSA during their hospitalization.  In this 
case, the test compared the proportions of the pre-and post-test participants of those that 
was admitted to the same acute care setting utilizing the Biopatch disc on admission 
within the organization.  To show the desired outcomes between the patients with and 
without the Biopatch disc the Fischer exact test of two proportions analysis was utilized.  
This test the hypothesis and showed that there may or may not be a difference between 
using the Biopatch disc in decreasing the incidence of MRSA in PIVs in patients that was 
admitted to acute care settings.  
The results of the categorical outcomes analysis enabled this scholar in accepting 
or rejecting the null hypothesis and after that offered an answer to the study question 
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regarding the effectiveness of the Biopatch disc in decreasing the incidence of MRSA in 
PIVs among patients who was admitted into the acute care setting.  The answer to the 
study question also assisted various stakeholders, including healthcare advocacies in 
designing surveillance programs and adherence to protocols that would further reduce 
patients the risks of HAIs in Jefferson County where the data was obtained. 
Summary 
In summary, there was much controversy over the best approach to tackling the 
problem of MRSA.  While targeted active surveillance was best reserved for high-risk 
patients or during times of an outbreak, adopting the simple perioperative strategies could 
lower the incidence of MRSA in PIVs in acute care settings.  Standardization of practice 
in acute care settings where patients are at increased risk for infections could be reduced 
by utilizing these practices.  If infection prevention is to be successful, all intricate staff 
and personnel must be involved in implementing those procedures and practices that 
reduces the risk of patients acquiring HAIs within their organization/facility. 
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Section 4: Findings and Recommendations 
The purpose of this project was to evaluate the utilization of the Biopatch disc on 
PIVs implemented in a hospital.  The Biopatch disc was a QI initiative aimed at reducing 
the incidence of MRSA in PIVs in patients admitted into the hospital acute care setting.  
The disciplinary team that was initiated at the project site to reduce HAIs discussed IP, 
QI, and RM hurdles.  Improving quality of care with the use of fewer resources can 
potentially help in reducing mortality and morbidity outcomes as well as health care costs 
(Austin et al. (2016).  The members of the healthcare team were informed of the QI 
initiative along with the pilot dates and organization-wide implementation dates.  Nursing 
staff was educated on the proper use and technique for utilizing the Biopatch disc and 
given an opportunity to provide feedback regarding the use and effectiveness of the disc 
in decreasing the incidence of MRSA in PIVs in patients admitted into acute care setting.   
I examined if the implementation of the Biopatch disc resulted in a reduction of 
MRSA in patients with PIVs.  The difference in the rate of MRSA in PIVs before and 
after the implementation of the Biopatch disc was examined and statistical significance 
was determined. Archival data of MRSA in 2016, the year prior to the implementation of 
the Biopatch disc, obtained from the IP, QI, and RM department was used as the pretest 
data. I also collected posttest data from after the implementation of the Biopatch disc. 
The pre- and posttest data were compared using the Chi-square test of two proportions.  I 
sought to answer the following practice question: In the acute care setting, did using the 
Biopatch disc reduce the risk of MRSA infection when used on PIVs over a 6-month 
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period?  In other words, in the acute care setting, did the hospital and nursing staff benefit 
from a 7-day peripheral IV protocol using the Biopatch disc over a 6-month period?   
The study time frame included a 1-year period from January 2016 through 
December 2016, during which the Biopatch disc was used.  This time frame was a year 
after the 30-day pretrial implementation of the initiative.  The data included the 
utilization of the Biopatch disc of patients in all inpatient units within the hospital. 
Findings and Implications 
PIVs insertion is a very common practice procedure among hospitalized patients 
within acute care settings, but there has been limited attention focused on the risks 
associated with PIVs infections.  The development of a QI program to evaluate and 
educate staff on the implementation of the Biopatch disc during the insertion of PIVs 
embraces this concept from an evidence-base best practice methodology.  According to 
Austin et al. (2016), the large number of PIVs that are placed annually means that the 
public health burden associated with this low-frequency event can be substantial.  
Subsequently, the Biopatch disc was implemented to help decrease the incidence of 
MRSA in PIVs within this organization.  The peer-reviewed literature only appraised the 
Biopatch disc being utilized with central venous catheter lines and peripherally inserted 
central catheters, but not with PIVs.  The evaluation program was developed to assist the 
IP, QI, and RM teams to help support the nursing staff in their ability to help detect and 
prevent patients from the increased incidence of developing MRSA in PIVs in acute care 
settings using the Biopatch disc. The intended outcome was to decrease the incidence of 
MRSA in PIVs in hospitalized patients admitted to acute care settings by utilizing the 
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Biopatch disc.  The educational initiative was designed to evaluate and validate the 
significance and importance of nurses to recognize and decrease the incidence of MRSA 
developing in PIVs.  It was essential that the primary focus of the evaluation program for 
nurses to be able to identify the signs and symptoms of developing infections in PIVs. 
Implementation 
Prior to the implementation of Phase I and Phase II, I developed a program 
timeline that outlined the required steps needed for the implementation of the Biopatch 
disc in the acute care setting.  The hospital had an existing process for implementing 
organizational systems projects.  The hospital chose to pilot the project first on a medical 
oncology unit for 30 days prior to implementing the project organization-wide. IP, RM, 
and QI looked at all patients who were admitted to the unit over the designated time 
frame who had a length of stay over seven days and were at increased risk for acquiring 
MRSA after receiving a PIV.  During the pretrial 30-day pilot month, the organization 
had a total of six MRSA incidents that manifested. The team looked at those patients, 
and, after reviewing the numbers founded on the results, started implementing the 
Biopatch disc in Phase I and Phase II organizational wide. 
Table 1 
Pre-Trial 30-day Pilot Month December 2015 
 Results 
 Biopatch disc No Biopatch-disc Marginal row totals  
MRSA  49 6 55  
# of Lines  176 127 303  
Marginal column 
totals  




One hundred and seventy-six patients were admitted on the medical oncology unit 
for the 30 days prior to implementing the Biopatch disc.  Of these patients, 49 (3.6%) 
used the Biopatch disc but had no incidence of MRSA compared to 127 patients (1.4%) 
who did not use the Biopatch disc. Due to the small sample sizes, Fischer’s exact test was 
run.  There was a statistically significant difference. The Fisher exact test statistic value 
was < 0.00001. The result is significant at p < .05. 
Phase I implementation plan was centered on the population sample that was 
chosen based on those patients that was admitted into the acute care setting and required 
a PIV during the 6-month trial period.  These patients were evaluated based on the 
incidence of acquiring MRSA during their hospitalization based on implementation of the 
Biopatch disc being utilized. The analysis was focused on the implementation of the 
Biopatch disc to reduce the rate of incidence of MRSA in PIV infections in the acute care 
setting of a local hospital in Jefferson County in Birmingham, Alabama in 2016.  Within 
the first 6 months of implementation, the median rate of infection was three, a rate that 
they could see slightly declining throughout the implementation of this project as seen in 
Table 2. 
Table 2 
Phase I- Implementation First Six Months Biopatch Disc January 2016-June 2016 
 Results 
 No Biopatch disc Biopatch disc Marginal row totals  
MRSA  34 3 37  
# of lines  240 206 446  
Marginal column 
totals  




During Phase I implementation of the Biopatch disc, there was 240 patients who 
was admitted to the medical Oncology unit, where 206 patients (7.1%) utilized the 
Biopatch disc showed no incidence of MRSA, when compared to the 34 patients (1.2%) 
who did not utilize the Biopatch. Though the sample size was small, but larger than the 
30-day pre-trial phase, a statistically significant could be seen when utilizing the Fischer 
exact test statistic value was < 0.00001. The result was significant at p < .05. 
During Phase I of the implementation of the project, the Biopatch disc was shown 
to make a slight decrease in reducing the incidence of MRSA during this time frame.  
The Fischer exact test of two proportions was used to analyze the data that had already 
been collected by the organization. This test showed that although the sample size was 
relatively small, there was a small statistically reduction in the proportions of patients to 
MRSA cases in the pre-trial 30-day Pilot month and the post implementation of Phase I 
of the Biopatch disc as seen in Table 3. 
Table 3 
Pre-trial 30-day Implementation Compared to Phase I Implementation of Biopatch Disc 
 Results 
   No Biopatch disc Biopatch disc Marginal row totals  
MRSA  6 240 246  
# of lines  176 3 179  
Marginal column 
totals  
182 243 425 (grand total)  
 
When the pre-trial 30-day implementation was compared to Phase I 
implementation of the Biopatch disc there could still be seen a slight statistical difference 
in the incidence of MRSA in those patients who utilized the Biopatch disc, versus those 
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patients who did not utilize the Biopatch disc in PIVs. Although, the difference was not 
all that great, it afforded the IP, QI, and RM team the opportunity to help decrease their 
incidence of MRSA in the future. The Fischer exact test value was <0.00001. The result 
was significant at p <0.05. 
In Phase II of the implementation of the project, there was seen a greater decrease 
in the incidence of MRSA in PIVs when the pre- trial implementation and Phase II of the 
project was analyzed using the Fischer exact test. When comparing the pre-trial month 
against Phase II a statistically significance could be seen in the decreased incidence of 
MRSA in PIVs as indicated in Table 4. If the Biopatch disc continues to be utilized, 
overtime it could prove to be very beneficial in decreasing the incidence of HAIs as it 
relates to PIVs. 
Table 4 
Phase II Implementation of Biopatch disc July 2016- December 2016 
 Results 
 No Biopatch disc Biopatch disc Marginal row totals  
MRSA  2 299 301  
# of lines  324 25 349  
Marginal column 
totals  
326 324 650 (grand total)  
 
During Phase II implementation of the Biopatch disc, there was 324 patients who 
was admitted to the medical Oncology unit, where 299 patients (99%) utilized the 
Biopatch disc and showed no incidence of MRSA, when compared to the 25 patients 
(1%) who did not utilize the Biopatch. Though the sample size had increased compared 
to the initial implementation of the Biopatch disc, a statistically significant could also be 
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seen when utilizing the Fischer exact test statistic value was <0.00001. The result was 
significant at p <.05. 
Table 5 shows that when the pre-trial 30-day Pilot month was compared to Phase 
II of the implementation of the Biopatch, there could be seen an even greater decline in 
the incidence of MRSA in PIVS in patients admitted to the acute care setting. 
Table 5 
Pre-trial 30-day Implementation Compared to Phase II Implementation of Biopatch Disc 
 Results 
 No Biopatch disc Biopatch disc Marginal row totals  
MRSA  6 324 330  
# of lines  176 2 178  
Marginal column 
totals  
182 326 508 (grand total)  
 
When the 30-day pre-trial utilization of the Biopatch disc implementation was 
compared to Phase II execution of the Biopatch disc, IP, QI, and RM determined that the 
incidence of MRSA in patients with PIVs could possibly be decreased through the 
utilization of the Biopatch disc. Although the sample sizes were small, there was the 
possibility that the Biopatch disc could possibly decrease the incidence of MRSA in those 
patients who were admitted in an acute care setting. The numbers were significant when 
utilizing the Fischer exact test, where the value could be <0.00001. The result was 
significant at p <.05. 
Important reductions in morbidity and health care cost could be achieved if the 
implementation of the Biopatch disc continues to prove fruitful in reducing the incidence 
of MRSA in PIVs.  The ability to measure and evaluate the true effectiveness of the 
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implementation of the Biopatch disc to decrease the incidence of MRSA in PIVs is still 
underdeveloped.  In this project, monitoring the rates of occurrence of MRSA in PIVs 
was possible because of the existence of the infrastructure of having an IP, QI and RM 
team who worked hand in hand in educating and training staff on the importance of 
hospital-based infection control practices.  Most importantly, the reduction in the 
morbidity and health care cost that could be achieved worldwide if the implementation of 
the Biopatch disc proved to be successful.  
Evaluation 
The evaluation plan was the biggest concern.  The data would not be collected 
until after implementation of each phase of the project.  The IP, QI, and RM team desired 
an evaluation plan that would include CLABSI, line days, patient days, CLABSI 
rate/1000 CL days and CL utilization ratio.  The evaluation showed that reducing the 
incidence of MRSA in PIVs using the Biopatch disc was feasible and could have a major 
impact on public health concerns.   The ability to measure and evaluate the effect of the 
project to increase patient safety remains underdeveloped.  In this evaluation project, 
monitoring catheter-related blood stream infections such as MRSA was possible because 
of the existence and strong commitment of the IP, QI, and RM team within the 
organization. 
According to Kettner et al. (2008), the primary purpose of the program evaluation 
was to provide feedback on the results or outcomes of the program impact to inform 
policy makers and planners about the effectiveness of the program or the appropriateness 
of the social intervention hypothesis that underlines them. Consequently, when 
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disseminating an evaluation plan, it was important to include key stakeholders for the 
program to be effective and attainable.  It was imperative to have developed a well-
designed and structured plan to help simplify the discovery of its success. 
The initial implementation of the program was evaluated against the development 
and contents from peer-reviewed literature, the primary evaluation was conducted at the 
end of a 12-month review by the IP, QI, and RM team.  This QI project provided an 
opportunity for increased awareness in decreasing the incidence of MRSA by using the 
Biopatch disc on PIVs for patients in acute care settings through education and training of 
staff on their use.  The program’s objective was to be able to show a steady decrease in 
the incidence of MRSA in PIVs through the implementation of the Biopatch disc within 
12-months.  The nurses on the unit were educated and trained on the proper use of the 
Biopatch disc and were asked to later provide feedback on the ease of use and the 
potential effectiveness in decreasing the incidence of MRSA in PIVs.  The feedback was 
intended to identify the effectiveness of the Biopatch disc, and whether the program 
captured the intention of the objectives and if the implementation of the Biopatch disc 
would have a successful transition into the clinical fold.  Finally, would the staff state that 
the implementation of the Biopatch disc would be successful and sustainable within the 
organization to improve patient’s outcomes and decrease the incidence of MRSA in 
PIVs?  Emphasis on the care and maintenance of catheters once they are inserted should 




Discussion of Findings in the Context of the Framework and Literature 
The findings showed that there was some statistical significance in the reduction 
of MRSA in PIVs using the Biopatch disc.  The Detection of Patient Risks by Nurses was 
the framework used to evaluate the Biopatch disc which was a QI project that involved 
decreasing the incidence of MRSA in PIVS of patients admitted in acute care settings.   
This process improvement project involved collaboration with clinical leaders, education/ 
in-services of inpatient areas. There were point prevalence follow-up to identify 
additional educational needs as they raised.   Small tests of change were used with the 
Biopatch disc starting in one unit which served as pilot for the initiative.  The Biopatch 
disc was carried out on the remaining units who implemented the initiative and the 
evaluation, innovation and spread.  QI projects involve continuous implementation, 
innovation and evaluation (Singh, et al., 2013).    The engagement of the staff in turn, 
could be influenced by lower patient satisfaction scores.  Leadership engagement 
likewise influenced by the potential for negative impact on patient safety and decrease 
quality of acre and patient outcomes.  Leadership and management should be able to 
maintain a constant purpose of improving quality (Zarbo, 2012).  The reduction of the 
MRSA can be attributed to other initiatives which was started before the Biopatch disc.   
Project Implications 
The implications for this project would serve as a catalyst to offer staff nurses the 
ability to be able to recognize the signs and symptoms of infection and help decrease the 
incidence of MRSA in patients with PIVs in acute care settings. PIV infections are a 
preventable source of MRSA.  Through the efforts of IP, QI, and RM in educating staff in 
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recognizing and monitoring PIVs by utilizing the Biopatch disc would help to decrease 
the incidence of this occurrence and help to decrease the incidence of MRSA.  According 
to Austin, et, al. (2016), suggests that site monitoring after the removal of PIVs should be 
a priority in preventive efforts.  More studies are needed in both to assess the incidence 
and burden of PIV-related blood stream infections and to evaluate effective innovative 
prevention strategies, such as checklists for PIV insertion, monitoring old PIV sites, or 
the use of anti-microbial- coated peripheral catheters. 
Implications of findings for individuals. The findings showed that there is 
statistical significance with the implementation of the Biopatch disc in reducing MRSA 
in PIVs of patients in acute care settings.  The Biopatch disc offered an important 
indicator on the importance of how to ensure optimal patient outcomes by initiating 
surveillance programs in acute care settings.  Healthcare in general and the nursing 
profession should advocate for the safety of the patients within their care.   
Implications for policy. The findings showed that there is some statistical 
significance with the implementation of the Biopatch disc in reducing MRSA in PIVs of 
patients in acute care settings.  The Biopatch disc increased the awareness of the IP, QI, 
and RM team that the Biopatch disc could make a difference in decreasing the incidence 
of MRSA in PIVs and therefore would warrant a change in hospital policy by 
incorporating the Biopatch disc in the hospital IV start kits. 
Implications for practice. The development of good practice guidelines with the 
implementation of the Biopatch disc could prove fruitful.  Educating and training 
personnel regarding the indications for the Biopatch disc in PIVs, proper procedure for 
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the use of the Biopatch disc and maintenance of IV catheters and appropriate infection 
control measures to prevent MRSA infections in PIVs could further decrease the 
incidence of occurrence when used properly.  Collaboration with IP, QI, and RM could 
increase performance improvement initiatives and further decrease the incidence of 
MRSA on PIVS and together improve hospital compliance. 
Implications for research. The Biopatch disc in decreasing MRSA in PIVs 
requires further research.  There have been numerous QI studies that have looked at the 
Biopatch disc on central venous lines, but limited research has been directed and focused 
on the Biopatch disc on PIVs.  The IP, QI, and RM team can potentially start a culture 
change wherein patients have a decrease incidence of MRSA in PIVs when they employ 
these multifaceted approaches in with several strategies and bundle together to improve 
compliance with the evidence-based guidelines. 
Implications of findings for systems. Healthcare systems should consider 
training for healthcare personnel on MRSA and how to decrease the incidence within 
their organization.  Increased collaboration among the health care team should be 
enhanced as they work towards decreasing HAIs of patients and providing greater patient 
outcomes.  The agency for Healthcare Research and Quality (AHRQ) has been 
supportive of the movement towards creating high reliability in healthcare to improve the 
quality and safety of care delivery (Blouin & McDonagh, 2011).  When safety and 
consistency is embedded in every aspect of performance it would ultimately decrease the 
number of infections within the organization. 
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Implications for positive social change. The Biopatch disc can potentially start a 
hospital culture change, wherein patients HAI infection rate can be reduced and lead to 
better patient outcomes and decrease length of stay. The Biopatch disc may provide local 
organizations/ acute care settings with the empowerment to make changes within their IP, 
QI, and RM departments to develop surveillance programs of their own to decrease their 
rates of MRSA in PIVs within their organization along with other HAIs initiatives.   
Recommendations 
There was a reduction of MRSA in PIVs of patients from 2015 to 2016 after the 
implementation of the Biopatch disc.  Based on the monthly results, there was still 
variations in the rate of infection that patients displayed in the hospital.  This could be 
diagnosis or technique-related and could be the seasons of the year when the rate of 
exacerbation of disease is greater.  There are other causes of suspension in the site 
monitoring before and after removal of the PIV that should have been a priority but was 
not able to be isolated.   
Although the data from this project did not measure the degree of reliability that the 
organization had hoped for, but the reliability could allow for other healthcare 
professionals and acute care settings organization, IP, QI, and RM teams to collaborate 
and develop local and regional surveillance programs that could be fruitful.  This project, 
along with other existing initiatives to educate nursing staff and other personnel on the 
incidence of decreasing MRSA in PIVs could prove sustainable. Furthermore, it could 
provide local hospital/acute care settings to be empowered to make the necessary changes 
within their IP, QI, and RM programs to develop a surveillance program of their own to 
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decrease their rates of MRSA in PIVS within their organization. Future research studies 
could be conducted, both to assess the true incidence and the burden of PIV-relate 
bloodstream infections and to evaluate effective innovative prevention strategies, such as 
checklists for PIV insertion, monitoring PIV sites and the use of qualified trained 
personnel in IV therapy.   
The information obtained from this study could provide additional knowledge on 
the reduction of MRSA using the Biopatch disc on PIVs of patients in acute care settings.  
Hospitals and health care systems could consider opportunities of improving progression 
of patient care and outcomes through collaboration of the health care team, IP, QI, and 
RM program in the acute care settings. Through these collaborative efforts hospitals and 
health care systems could decrease its HAIs rates and improve their overall patient 
outcomes as well as decrease patients’ length of stay, mortality, and morbidity rates. 
Strengths and Limitations of the Project 
Strengths 
The strengths of this DNP Project were that by using the Biopatch disc, the 
organization’s QI initiative was able to increase patients’ outcomes and place them at the 
center of good quality care.  The project was evidence-based and proved to be successful 
by the nursing staff.  The project was validated by the IP, QI, and RM team in the field of 
QI as it relates to patient care and outcomes. 
Limitations 
The evaluation did have some limitations.  First, potential under reporting of 
MRSA infections and the lack of baseline data from the units that immediately 
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implemented the intervention when the evaluation was implemented could have created a 
measurement prejudice that inflated the results.  However, the infection rates were 
collected and reported by the hospital IP, QI and RM team who were impartial of the unit 
staff implementing the intervention.  Second, they did not evaluate compliance with the 
project intervention, because of limited resources that prevented the observation of PIVs 
placement.  Lastly, the data on the organisms that caused the MRSA or catheter related 
blood stream infection were not collected, limiting the insight into the mechanism of the 
observed benefit of utilizing the Biopatch disc. 
Summary 
The implementation of the Biopatch disc on PIVs would serve as one way to help 
decrease the incidence of MRSA in PIVs in patients in acute care settings.  There is still 
much debate over the best approach to undertaking the problem of MRSA.  If infection 
prevention is to be successful, all concerned staff and personnel must be involved in 
implementing these procedures and practices that can help reduce the incidence of patient 
acquiring HAIs within their organization. 
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Section 5: Dissemination Plan 
Healthcare arenas are discovering ways to reduce HAIs due to the increasing 
length of stay and the related increase in healthcare costs and changes as they relate to the 
reimbursement process from payee resources (Mutter, 488).  Dissemination of the results 
of the project started in the hospital where the Biopatch disc was implemented.  The first 
to be informed will be the medical oncology unit nurse manager and nursing staff so that 
the team and managers who were influential in the implementation of the QI initiative 
will be informed of the results.  Another setting was the IP, QI, and RM team meeting to 
provide them with the information on the changes that were the result of their initiative. 
I plan to disseminate findings from this project to the broader IP, QI, and RM 
community through a Power Point presentation at one of the yearly Healthcare 
conferences so that other organizations will be informed of the QI project.  For a wider 
audience, the project was presented to the organization of hospital QI and RM through its 
website.  This dissemination provided information to other organizations who were 
considering ways to reduce their number of HAIs as it related to MRSA and PIVs. 
Analysis of Self 
I began this project as I was recovering from a knee injury that resulted in major 
complications at the hospital.  I have been a staff nurse for 18 years and a classroom and 
clinical instructor, so my involvement in the hospital was not limited to just this area.  
When I became a nurse, I was groomed to be an educator and introduced to other clinical 
educators and clinical leaders who advocated for health promotion and disease 
prevention.  I was recovering, and when the Biopatch disc was conceptualized and 
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implemented, I was a participant in the initiative without my knowledge.  I witnessed 
how this QI initiative was carried out and saw how IP, QI, and RM interacted with the 
nurse managers and nursing staff to improve patients’ outcomes and quality of care. 
The biggest challenge in completing this project was recovering from surgery, 
sickness, and the death of a spouse and balancing time between work, school, and family.  
My hospital has been going through many changes and challenges including being 
bought out and merged with another organization.  Completing this project was also 
affected by the preterm birth of my first grandchild.  I spent plenty of sleepless nights 
waiting on the phone to ring with more bad news and prognosis.  I also spent time 
relearning statistics, which was very perplexing for me, while analyzing and interpreting 
the data. 
This DNP project has taught me that I should always follow my heart and focus 
my goals on those things that I desire and make me uniquely and wonderfully interesting 
to those who cross my path.  I have realized that anything in this life that I want, I must 
set goals to attain and allot plenty of time, money, and energy to achieve.  I have also 
recognized that as an advanced practice nurse, I am expected to lead and guide others into 
making the best decisions as they relate to the patients we advocate for daily.  Best of all, 
this project has taught me to never give up on my dreams and never to accept defeat as 





This DNP project was an evaluation of the Biopatch disc QI initiative that was 
implemented to reduce the incidence of MRSA in PIVs for patients in the acute care 
project setting.  I evaluated whether there was a statistically significant difference in the 
reduction of MRSA with the implementation of the Biopatch disc compared to PIVs 
without the Biopatch disc.  Project findings showed that there were some statistical 
differences between MRSA and the Biopatch disc.  Although the findings showed some 
statistical differences, the reduction of MRSA in PIVs cannot be fully attributed to the 
Biopatch disc as there could have been other changes that emerged which could have 
affected the findings.   
The information acquired in this project can be used and tried at another 
organization to see whether it would produce similar results.  The Biopatch disc should 
be included for consideration in other recommended bundles of professional 
organizations and for use on PIVs. This would offer information to these organizations 
who are considering ways of decreasing their incidence of HAIs as it relates to MRSA 





Altman, D. G., Machin, D., Bryant, T. N., & Gardner M.J. (Eds.). (2000). Statistics with 
confidence (2nd ed.). British Library Cataloguing in Publication Data, BMJ 
Books.  
Austin, E. D., Sean, S. B., Whittier, S., Lowy, F. D., & Uhlemann, A. (2016, February 
11). Peripheral intravenous catheter placement is an underrecognized source of 
Staphylococcus aureus bloodstream infection. Open Forum Infectious Diseases, 
3(2). http://dx.doi.org/10.1093/ofid/ofw072 
Blouin, A. S., & McDonagh, K. J. (2011). Framework for patient safety, Part 1: Culture 
as an imperative. Journal of Nursing Administration, 41(10), 397-400. doi: 
10.1097/NNA.0b013e31822edb4d  
Burns, N., & Groves, S. K. (2009). The practice of nursing research: Appraisal, 
synthesis, and generation of evidence (6th ed.). St. Louis, MO: Saunders Elsevier. 
Byrne, C., Hazlerigg, A., Khan, W., & Smitham, P. (2011, December). The role of 
perioperative care in reducing rates of methicillin resistant Staphylococcus aureus. 
The Journal of Perioperative Practice, 21(12), 410. Retrieved from Nursing & 
Allied Health database. 
Campbell, I. (2007). Chi-squared and Fisher-Irwin tests of two-by-two tables with small 
sample recommendations. Statistics in Medicine, 26, 3661-3675.  doi: 
10.1002/sim.2832.PMID: 17315184. 
Cooke, H. (2009). Theories of risk and safety: What is their relevance to nursing. Journal 




Coopersmith, C., Rebmann, T., & Zack, J. (2002). Effect of an education program on 
decreasing catheter-related bloodstream infections in the surgical intensive care 
unit. Critical Care Medicine, 30(1), 59-64. https://doi.org/10.1016/S1036-
7314(02)80053-4  
Curns, A., Holman, R., Sejvar, J., Owens, M., & Schonberger, L. (2005). Infectious 
disease hospitalizations among older adults in the United States from 1990 
through 2002. Archive of Internal Medicine, 165(21), 2514-2520. doi: 
10.1001/archinte.165.21.2514.  
Currie, K., Knussen, C., Price, L., & Reilly, J. (2013). Methicillin-resistant 
Staphylococcus aureus screening as a patient safety initiative: using patient’s 
experiences to improve the quality of screening practices. Journal of Clinical 
Nursing, 23, 221-231. http://dx.doi.org/10.1111/jocn.12366 
Daley, J. E., Pronovost, P. J., Needham, D. M., & Berenholtz, S. (2007). Catheter-related 
bloodstream infections. The New England Journal of Medicine, 356(12), 1267-
1268. http://dx.doi.org/10.1056/NEJMc070179 
DeVries, M., Mancos, P. S., & Valentine, M. J. (2014). Reducing bloodstream infection 
risk in central and peripheral intravenous lines: Initial data on passive intravenous 
connector disinfection. Journal of the Association for Vascular Access, 19(2), 87-
93. http://dx.doi.org/10.1016/j.java.2014.02.002 
Donlan, R. (2008). Biofilms on central venous catheters: is eradication possible? Current 




Elliott, T. (1993). Line-associated bacteremias. CDR: Reviews, 3(7), R91-R96. 
General Information About MRSA in Healthcare settings. (2017). Retrieved February 16, 
2017, from https://www.cdc.gov/mrsa/healthcare/index.html 
Hadaway, L. (2012, July/August). Short Peripheral Intravenous Catheters and Infections. 
Journal of Infusion Nursing, 35(4), 230-240. 
http://dx.doi.org/10.1097/NAN.0b013e31825af099 
Hospital profile. (2017). Retrieved February 16, 2017, from 
https//www.medicare.gov/hospitalcompare/profile.html#profTab=3&... 
Jamal, M., Rosenblatt, J., & Hachem, R. (2013). Prevention of Gram-negative bacterial 
biofilm on minocycline/rifampin impregnated catheters sequentially coated with 
chlorhexidine. Antimicrobial Agents Chemotherapy, 58(2), 1179-1182 
Jeanne, Z. (2008). Zeroing in on zero tolerance for central line-associated bacteremia. 




Kettner, P. M., Moroney, R.M., & Martin, L.L. (2008). Designing and Managing 
programs: An effectiveness-based approach (3rd Ed). Thousand Oaks, CA: Sage. 
Laerd Statistics. (2016). Statistical tutorials and software guides. Retrieved from 
https://statistics.laerd.com.  
Masters, K. (2012). Nursing Theories: A framework for professional practice. Sudbury, 
48 
 
MA: Jones & Barlett Learning, LLC. 
Mutters, N. T., Gunther, F., Heininger, A., & Frank, U. (2014, April). Device-related 
infections in long-term healthcare facilities: the challenge of prevention. Future 
Microbiology, 9(4), 487-495. Retrieved from 
http://search.proquest.com.ezp.waldenlibrary.org/docview/1522684612?accountid
=14872# 
Polit, D. F. (2010). Statistics and Data Analysis for Nursing Research (2nd ed.). Saratoga 
Springs, New York: Human analysis, Inc. 
Polonsky, M.S. (2019). High-Reliability Organizations: The Next Frontier in Healthcare 
Quality and Safety. Journal of Healthcare Management, [s. l.], v. 64, n. 4, p. 213–
221, 2019. DOI 10.1097/JHM-D-19-00098. 
Pronovost, P., Needham, D., Berenholtz, S., Sinopoli, D., Chu, H., Cosgrove, S., ... 
Goeschel, C. (2006, December 28). An Intervention to Decrease Catheter-Related 
Bloodstream Infections in the ICU. The New England Journal of Medicine, 
355(26), 2725-2732. Retrieved from 
Raad, I., Reitzel, R., Jiang, Y., Chemaly, R., Dvorak, T., & Hachem, R. (2008). Anti-
adherence activity and antimicrobial durability of anti-infective-coated catheters 
against multidrug-resistant bacteria. Journal of Antimicrobial Chemotherapy, 
62(4), 746-750. 
Richardson JTE (2011) The analysis of 2 x 2 contingency tables - Yet again. Statistics in 
Medicine 30:890. DOI: 10.1002/sim.4116 
Serane, T., & Kothendaraman, B. (2016, February 23). Incidence and risk factors of 
49 
 
infections associated with peripheral intravenous catheters. Journal of Infection 
Prevention, 17(3), 115-120. http://dx.doi.org/10:1177/1757177416631415 
Singh, K., Sanderson, J., Galarneau, D., Keister, T. & Hickman, D. (2013). Quality 
improvement on the acute inpatient psychiatry unit using the model for 
improvement. The Ochsner Journal, 13(3), 380-84.  
Waghorn, D. (1994). Intravascular device-associated systematic infections: a two-year 
analysis of cases in a district general hospital. Journal of Hospital Infection, 
28(2), 91-101. 
Warren, D., Cosgrove, S., & Diekema, D. (2006). A multicenter intervention to prevent 
catheter-associated bloodstream infections. Infection Control Hospital of 
Epidemiology, 27(7), 662-669. 
Zarbo, R. (2012). Creating and sustaining a lean culture of continuous process 
improvement. American Journal of Clinical Pathology, 138 (3), 321-326. 
